About

Time: May 27, 11 am EST
Presenter: CEO Tero-Pekka Alastalo (MD, PhD)

As mRNA therapeutics expand beyond vaccines into antibodies, cytokines, enzymes, and other secreted biologics, optimizing every sequence element becomes increasingly important for performance and manufacturability.

Yet while codon usage, untranslated regions, and lipid delivery systems receive attention, signal peptides remain an underutilized lever in mRNA design. These short N-terminal sequences determine how efficiently newly translated proteins enter the secretory pathway, influencing expression levels, secretion efficiency, product quality, and ultimately cost of production.

In this webinar, we will explore how signal peptide engineering is emerging as a powerful strategy to improve mRNA therapeutics. Drawing from published scientific literature and real-world case studies, we will examine how signal peptide selection can significantly enhance antigen expression, immune responses, and production efficiency. We will also discuss why native signal peptides are not always optimal, and how rational design, high-throughput screening, and machine learning are enabling the discovery of better-performing alternatives.

This webinar covers:

• Understand the role of signal peptides in the development of mRNA therapies
• Learn why native signal peptides may not be optimal for mRNA-based biologics
• Discover how high-throughput engineering accelerates candidate selection

The webinar will be recorded and made available to attendees after the webinar.